There are 2949 resources available
1269P - EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Byoung Yong Shim
Session: E-Poster Display
Resources:
Abstract
1270P - IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: E-Poster Display
Resources:
Abstract
1271P - 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract
1272P - Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: E-Poster Display
Resources:
Abstract
1273P - Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial
Presenter: Fabrice Barlesi
Session: E-Poster Display
Resources:
Abstract
1274P - First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
Presenter: Kenneth O'Byrne
Session: E-Poster Display
Resources:
Abstract
1275P - Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Presenter: Maria Gonzalez Cao
Session: E-Poster Display
Resources:
Abstract
1276P - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
Presenter: Jean-Baptiste Assié
Session: E-Poster Display
Resources:
Abstract
1277P - An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Carlo Genova
Session: E-Poster Display
Resources:
Abstract
1278P - Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Roberto Ferrara
Session: E-Poster Display
Resources:
Abstract